Company intelligence / Profile preview

Chengdu Origen Biotechnology Co., Ltd.

Chengdu, Sichuan, Chinanature.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Currently conducting two Phase 1 clinical trials: VAN-2201 evaluating KH631 (first patient dosed in November 2023) and VAN-2401 evaluating KH658 (first patient dosed in May 2025) for wet AMD. Both therapies are designed to deliver anti-VEGF continuously to the retina with potential for sustained disease control through single administration.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyAAV-based gene therapy
Industry: Biotech

Drug pipeline

4 assets

KH658

3 more assets in the full pipeline.

Request access →

Partnerships

Vanotech Ltd.

Beyond the preview

Go deeper on Chengdu Origen Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Origen Biotechnology Co., Ltd..

Explore the full profile